Dopavision Appoints Dr Dirk Sauer as Chair of the Company s Advisory Board streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Novartis Pharma AG: Novartis Phase III Beovu data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
1
More patients treated with Beovu 6 mg experienced fluid (IRF/SRF) resolution at week 32 and week 52 versus aflibercept; fluid is a key marker of disease activity in DME
1
1
Phase III KESTREL and KITE trials are the first pivotal trials to assess an anti-VEGF on six-week dosing intervals in the loading phase, suggesting Beovu may offer fewer injections from the start of treatment
1
Novartis is committed to bringing Beovu 6 mg to DME patients and will submit data from KESTREL and KITE to global health authorities in H1 2021
NOVARTIS AG CHF0.50(REGD)
Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
In KESTREL and KITE, Beovu (brolucizumab) 6 mg met the primary endpoints of non-inferiority in change in best corrected visual acuity from baseline versus aflibercept 2 mg at year one in diabetic macular edema (DME) patients
1
More patients treated with Beovu 6 mg experienced fluid (IRF/SRF) resolution at week 32 and week 52 versus aflibercept; fluid is a key marker of disease activity in DME
Analysis Of The Non-alcoholic Steatohepatitis (NASH) Drug Pipeline & Market: The M&A And Commercial Landscape
By Mavra Nasir, Ph.D., Crystal Hsu, and Peter Bak, Ph.D., Back Bay Life Science Advisors
In Part 1 and Part 2 of this three-part series, we covered the varied complexities of NASH driving an extremely challenging development landscape, along with the growing prevalence of NASH that has the life sciences industry in a race to develop a successful asset.
In this last part of the series, we cover the M&A and commercial landscape implications, including historical and future deal trends, challenges in developing a successful commercial strategy, and what to watch out for as the NASH industry continues to reach new milestones.